Does GLP-1 Cause Hair Loss? What the Research Actually Shows

Direct Answer

Yes, real, extensive, convergent research from multiple large, independent studies has found a genuine association between GLP-1 medications and increased hair loss risk, particularly with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). The FDA has been informed of this signal and is actively evaluating it.

The Real, Substantial Evidence

A July 2026 BMJ study of roughly 50,000 people found GLP-1 use associated with a 37% increased risk of alopecia compared to SGLT-2 inhibitor diabetes medications. A separate study in the Journal of the American Academy of Dermatology, covering more than 1 million participants, found significantly higher rates of various alopecia subtypes with GLP-1s than with metformin. Multiple additional pharmacovigilance analyses (using FDA's FAERS database) and systematic reviews independently support the same real pattern.

What Type of Hair Loss This Actually Is

The two most commonly reported subtypes are telogen effluvium (temporary, diffuse shedding, often linked to rapid weight loss itself, not necessarily the drug directly) and androgenetic alopecia (pattern hair thinning). Research suggests tirzepatide is more frequently linked to telogen effluvium specifically, while semaglutide's association appears real, if dose-dependent, doses under 2mg weekly are rarely implicated, with higher, obesity-treatment-level doses showing more association.

Who Appears More Affected

Research indicates females are disproportionately affected. Rapid weight loss itself is considered a real, plausible contributing mechanism, meaning the hair loss may relate to the pace and magnitude of weight change as much as to the medication directly.

A Real, Important Reassurance Worth Knowing

Despite the statistically significant relative risk increase found across these studies, researchers consistently emphasize that the absolute risk of hair loss remains low. This is a real, meaningful, but genuinely uncommon side effect, worth knowing about, not something to expect as a certainty.

Bottom Line

This is a real, well-documented, increasingly studied safety signal, not speculation, though still actively being researched to better understand the exact mechanism and who's most at risk. If you notice hair thinning or shedding while on a GLP-1 medication, it's worth mentioning directly to your provider.

References

• The BMJ: GLP-1 receptor agonists and risk of alopecia (July 22, 2026)
• Journal of the American Academy of Dermatology: GLP-1 medications and alopecia subtype risk
• Gupta, A.K., et al., "GLP-1 Therapies and Hair Loss: A Systematic Review of Current Evidence" (2026)

Related Resources

• Does Retatrutide (GLP-3) Cause Hair Loss?

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice.